ClinVar Miner

Submissions for variant NM_000051.3(ATM):c.6179G>A (p.Arg2060His) (rs376521407)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000122869 SCV000166127 uncertain significance Ataxia-telangiectasia syndrome 2018-12-12 criteria provided, single submitter clinical testing This sequence change replaces arginine with histidine at codon 2060 of the ATM protein (p.Arg2060His). The arginine residue is moderately conserved and there is a small physicochemical difference between arginine and histidine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in an individual affected with breast cancer (PMID: 12673797). However, in that individual a pathogenic allele was also identified in ATM (phase unknown), which suggests that this c.6179G>A variant was not the primary cause of disease. ClinVar contains an entry for this variant (Variation ID: 135765). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV000131768 SCV000186814 likely benign Hereditary cancer-predisposing syndrome 2018-02-13 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Co-occurence with mutation in same gene (phase unknown),In silico models in agreement (benign)
GeneDx RCV000212041 SCV000209791 uncertain significance not provided 2018-09-21 criteria provided, single submitter clinical testing This variant is denoted ATM c.6179G>A at the cDNA level, p.Arg2060His (R2060H) at the protein level, and results in the change of an Arginine to a Histidine (CGC>CAC). This variant was observed in an individual with breast cancer and in an individual with prostate cancer (Bernstein 2003, Carneiro 2018). ATM Arg2060His was not observed in large population cohorts (Lek 2016). This variant is located in the FAT domain (Stracker 2013). In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether ATM Arg2060His is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Color RCV000131768 SCV000687677 uncertain significance Hereditary cancer-predisposing syndrome 2018-07-24 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000779793 SCV000916596 uncertain significance not specified 2018-09-24 criteria provided, single submitter clinical testing Variant summary: ATM c.6179G>A (p.Arg2060His) results in a non-conservative amino acid change located in the PIK-related kinase domain (IPR014009) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant was absent in 276988 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. The variant, c.6179G>A, has been reported in the literature in one individual affected with breast cancer in whom another ATM variant reported as 6405insTT was identified (Bernstein_2003). The phase of these variants were not provided in this report. This report does not provide unequivocal conclusions about association of the variant with Ataxia-Telangiectasia (A-T). Co-occurrences with other pathogenic variants have been reported (ATM c.6404_6405insTT reported in the literature as well as an internal specimen with phase unknown), providing supporting evidence for a benign role in the context of breast cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (VUS x3, likely benign x1). Based on the evidence outlined above, the variant was classified as uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.